Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a Phase l study

A phase l study using intravesical Ad-IFNα/Syn3 for patients with BCG resistant superficial bladder cancer showed a complete remission (CR) of 43% at 90 days after treatment with high levels of IFNα being produced. Ad-IFNα kills bladder cancer cells by two apoptotic and one necrotic mechanism that c...

Descripción completa

Detalles Bibliográficos
Autores principales: Benedict, William F., Fisher, Mark, Zhang, Xin-qiao, Yang, Zhibo, Munsell, Mark F., Dinney, Colin N.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962717/
https://www.ncbi.nlm.nih.gov/pubmed/24503570
http://dx.doi.org/10.1038/cgt.2014.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3962717/
https://www.ncbi.nlm.nih.gov/pubmed/24503570
http://dx.doi.org/10.1038/cgt.2014.1

Ejemplares similares